Genova
Italy
University of Genova - Department of Internal Medicine and Medical Specialties (DiMI)
HR+/HER2- metastatic breast cancer, CDK4/6 inhibitor resistance, Systematic Review, Network meta-analysis, Biomarker-driven therapy, Antibody-drug conjugates
HR+/HER2- advanced breast cancer, CDK4/6 inhibitors, Real-world, progression-free survival, Lobular histology, PALMARES-2
Ovarian function suppression, HER2 positive, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, LHRH agonists, neoadjuvant, residual disease, pathological complete response
Breast Cancer, Clinical Trials, Contraception, Quality of Life
Gonadotropin-releasing hormone agonist, Hormone receptor-positive early breast cancer, Aromatase Inhibitor, Ovarian Suppression, Adjuvant endocrine treatment, Premenopausal